Interaction Checker

Interaksi Lapatinib

Lapatinib (Tykerb), golongan penghambat P-glikoprotein, memiliki 174 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 89 mayor, 74 moderat, 11 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (89)

  • AdenosinantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • AmiodaronantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • Aprepitantpenghambat CYP3A4Mayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Armodafinilstimulan SSPMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • AtazanavirantiretroviralMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Mayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • DabigatranantikoagulanMayor

    Avoid use of PRADAXA Capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) [see Drug Interactions (7.1) and Use in Specific Populations (8.6) ] . (label Dabigatran, Peringatan dan perhatian)

  • DarunavirantiretroviralMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Deferasirokssuplemen zat besiMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • Digoksinglikosida digitalisMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • Diltiazempenghambat kanal kalsiumMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • DisopiramidantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • DofetilidantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • DronedaronantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • EfavirenzantiretroviralMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Eritromisinantibiotik makrolidaMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • EslikarbazepinantikonvulsanMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • Esmololpenyekat betaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • EtravirinantiretroviralMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • EverolimusimunosupresanMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • FenitoinantikonvulsanMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • FenobarbitalbarbituratMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • FlekainidantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • Flukonazolantijamur azolMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • FosamprenavirantiretroviralMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Mayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • FosfenitoinantikonvulsanMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • GriseofulvinantijamurMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • IbutilidantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • Imatinibpenghambat CYP3A4Mayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • IsoniazidantibiotikMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Itrakonazolantijamur azolMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Mayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • KapesitabinantimetabolitMayor

    In animal reproductive studies, administration of lapatinib to pregnant rats during the period of organogenesis and through lactation led to death of offspring within the first 4 days after birth at maternal exposures that were ≥ 3.3 times the human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine. (label Lapatinib, Peringatan dan perhatian)

  • KarbamazepinantikonvulsanMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • Ketokonazolantijamur azolMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Klaritromisinantibiotik makrolidaMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • KlobazambenzodiazepinMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • KolkisinMayor

    P-glycoprotein The concomitant use of colchicine capsules and inhibitors of P-glycoprotein (e.g. clarithromycin, ketoconazole, cyclosporine, etc.) should be avoided due to the potential for serious and life-threatening toxicity [see Warnings and Precautions (5.3) and Clinical Pharmacology (12) ] . (label Kolkisin, Interaksi obat)

  • KuinidinantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • LenakapavirantiretroviralMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Lidokainanestetik lokalMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • Lidokain dan prilokainanestetik lokalMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • Lopinavir dan ritonavirantiretroviralMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Mayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • MeksiletinantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • Mifepristonpenghambat CYP3A4Mayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Mirabegronagonis beta-adrenergikMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Mayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • Modafinilstimulan SSPMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • NefazodonantidepresanMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • NevirapinantiretroviralMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • OkskarbazepinantikonvulsanMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Mayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • PazopanibMayor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (label Pazopanib, Interaksi obat)

  • PerampanelantikonvulsanMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Posakonazolantijamur azolMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • PrimidonantikonvulsanMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • ProkainamidantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • PropafenonantiaritmiaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • Ranolazinobat yang memperpanjang interval QTMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • RifabutinantibiotikMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • RifampisinantibiotikMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • RifapentinantibiotikMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • RimegepantMayor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (label Rimegepant, Interaksi obat)

  • RitonavirantiretroviralMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • SenobamatantikonvulsanMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • SiklosporinimunosupresanMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • SirolimusimunosupresanMayor

    • Avoid concomitant use with strong CYP3A4/P-gp inducers or strong CYP3A4/P-gp inhibitors that decrease or increase sirolimus concentrations ( 7.4 , 12.3 ). (label Sirolimus, Interaksi obat)

  • Sofosbuvir dan velpatasvirantivirusMayor

    Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (label Sofosbuvir dan velpatasvir, Interaksi obat)

  • Sotalolpenyekat betaMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • Suvoreksantsedatif-hipnotikMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Mayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • TalazoparibMayor

    Effect of Other Drugs on TALZENNA Effect of P-gp Inhibitors Breast Cancer Avoid coadministration of TALZENNA with the following P-gp inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil. (label Talazoparib, Interaksi obat)

  • TikagrelorantiplateletMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

  • TopiramatantikonvulsanMayor

    Avoid strong CYP3A4 inducers. (label Lapatinib, Interaksi obat)

  • TopotekanMayor

    Avoid concomitant use HYCAMTIN capsules with P-gp inhibitors or BCRP inhibitors. (label Topotekan, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • VinkristinMayor

    Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (label Vinkristin, Interaksi obat)

  • Vorikonazolantijamur azolMayor

    Avoid strong CYP3A4 inhibitors. (label Lapatinib, Interaksi obat)

Interaksi moderat (74)

  • AfatinibModerat

    P-glycoprotein (P-gp) Inhibitors : Co-administration of P-gp inhibitors can increase afatinib exposure. (label Afatinib, Interaksi obat)

  • Alfuzosinpenyekat alfaModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Amitriptilinantidepresan trisiklikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Anagrelidobat yang memperpanjang interval QTModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Arsen trioksidaobat yang memperpanjang interval QTModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • AsenapinantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Azitromisinantibiotik makrolidaModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Dekslansoprazolpenghambat pompa protonModerat

    However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (label Lapatinib, Interaksi obat)

  • Dekstrometorfan dan kuinidinobat serotonergikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Deutetrabenazinpenghambat VMAT2Moderat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Droperidolantagonis dopaminModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • EdoksabanantikoagulanModerat

    P-gp Inhibitors Treatment of NVAF Based on clinical experience from the ENGAGE AF-TIMI 48 study, dose reduction in patients concomitantly receiving P-gp inhibitors resulted in edoxaban blood levels that were lower than in patients who were given the full dose. (label Edoksaban, Interaksi obat)

  • Eltrombopagpenghambat OATP1B1Moderat

    …(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (label Eltrombopag, Interaksi obat)

  • Emtrisitabin dan tenofovirantiretroviralModerat

    Coadministration of DESCOVY with other drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentration of TAF. (label Emtrisitabin dan tenofovir, Interaksi obat)

  • EsitalopramSSRIModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Esomeprazolpenghambat pompa protonModerat

    However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (label Lapatinib, Interaksi obat)

  • Fidaksomisinantibiotik makrolidaModerat

    Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated adult patients in controlled clinical trials. (label Fidaksomisin, Interaksi obat)

  • FingolimodimunosupresanModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • FluoksetinSSRIModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Granisetronobat yang memperpanjang interval QTModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • HaloperidolantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Hidroksiklorokuinobat yang memperpanjang interval QTModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • HidroksizinantihistaminModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • IloperidonantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • KlorokuinantimalariaModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • KlorpromazinantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • KlozapinantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • KuetiapinantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • KuininantimalariaModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Lansoprazolpenghambat pompa protonModerat

    However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (label Lapatinib, Interaksi obat)

  • LevofloksasinfluorokuinolonModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • LomitapidModerat

    …Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (label Lomitapid, Interaksi obat)

  • Loperamidobat yang memperpanjang interval QTModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • MetadonopioidModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • MidazolambenzodiazepinModerat

    Midazolam : Following coadministration of TYKERB and midazolam (CYP3A4 substrate), 24-hour systemic exposure (AUC) of orally administered midazolam increased 45%, while 24-hour AUC of intravenously administered midazolam increased 22%. (label Lapatinib, Interaksi obat)

  • MoksifloksasinfluorokuinolonModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • MorfinopioidModerat

    P-Glycoprotein (P-gp) Inhibitors Clinical Impact: The concomitant use of P-gp inhibitors can increase the exposure to morphine by two-fold and can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. (label Morfin, Interaksi obat)

  • Naldemedinantagonis opioidModerat

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (label Naldemedin, Interaksi obat)

  • Naproksen dan esomeprazolOAINSModerat

    However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (label Lapatinib, Interaksi obat)

  • Nilotinibobat yang memperpanjang interval QTModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • OfloksasinfluorokuinolonModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Olanzapin dan fluoksetinantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Omeprazolpenghambat pompa protonModerat

    However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (label Lapatinib, Interaksi obat)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonModerat

    However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (label Lapatinib, Interaksi obat)

  • Ondansetronobat yang memperpanjang interval QTModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • PaklitakselModerat

    Paclitaxel : In cancer patients receiving TYKERB and paclitaxel (CYP2C8 and P-gp substrate), 24-hour systemic exposure (AUC) of paclitaxel was increased 23%. (label Lapatinib, Interaksi obat)

  • PaliperidonantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Pantoprazolpenghambat pompa protonModerat

    However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (label Lapatinib, Interaksi obat)

  • Pentamidinobat yang memperpanjang interval QTModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • PimavanserinantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • PimozidantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Pitolisantobat yang memperpanjang interval QTModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • PrometazinantihistaminModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Prometazin dan dekstrometorfanantihistaminModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Prometazin dan kodeinopioidModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Rabeprazolpenghambat pompa protonModerat

    However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (label Lapatinib, Interaksi obat)

  • RifaksiminantibiotikModerat

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (label Rifaksimin, Peringatan dan perhatian)

  • RisperidonantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • SiprofloksasinfluorokuinolonModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • SitalopramSSRIModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • SolifenasinantikolinergikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • TakrolimusimunosupresanModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Tamoksifenmodulator reseptor estrogen selektifModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Tetrabenazinpenghambat VMAT2Moderat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • TioridazinantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • TolterodinantikolinergikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Toremifenmodulator reseptor estrogen selektifModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • TramadolopioidModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Tramadol dan parasetamolopioidModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • TrazodonantidepresanModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Valbenazinpenghambat VMAT2Moderat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Vardenafilpenghambat PDE5Moderat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • VenlafaksinSNRIModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • ZiprasidonantipsikotikModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

Penyebutan minor (11)

  • Biktegravir, emtrisitabin, dan tenofovir alafenamidantiretroviralMinor

    Lenacapavir (LEN), a component of BIXLENVO, is a moderate inhibitor of CYP3A and a P-gp inhibitor. (label Biktegravir, emtrisitabin, dan tenofovir alafenamid, Interaksi obat)

  • Dapagliflozinpenghambat SGLT2Minor

    Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. (label Dapagliflozin, Interaksi obat)

  • EribulinMinor

    Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (label Eribulin, Interaksi obat)

  • Famotidinpenghambat H2Minor

    Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (label Lapatinib, Interaksi obat)

  • Ibuprofen dan famotidinOAINSMinor

    Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (label Lapatinib, Interaksi obat)

  • MeflokuinantimalariaMinor

    Substrates and Inhibitors of P-glycoprotein It has been shown in vitro that mefloquine is a substrate and an inhibitor of P-glycoprotein. (label Meflokuin, Interaksi obat)

  • Natrium bikarbonatantasidaMinor

    Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (label Lapatinib, Interaksi obat)

  • Nizatidinpenghambat H2Minor

    Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (label Lapatinib, Interaksi obat)

  • Ranitidinpenghambat H2Minor

    Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (label Lapatinib, Interaksi obat)

  • Silodosinpenyekat alfaMinor

    Strong P-glycoprotein (P-gp) Inhibitors In vitro studies indicated that silodosin is a P‑gp substrate. (label Silodosin, Interaksi obat)

  • VepdegestrantMinor

    Mechanism and Clinical Effect(s) Vepdegestrant is a P-gp inhibitor. (label Vepdegestrant, Interaksi obat)

Periksa Lapatinib terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.